Asthma
Conditions
Interventions
This is a randomized controlled clinical study with two arms, double-blind. The pilot study will be conducted for 15 days, during which approximately 10 patients are intended to be included. This stag
Umeclidinium bromide + vilanterol trifenatate (62.5mcg + 25mcg), Ellipta© System with inhalable powder (DI2)
Tiotropium monohydrate bromide + olodaterol hydrochloride (2.5mcg + 2.5mcg), Respimat© System with pressurized solution (DI3). Pharmaceutical Guidance: Pharmaceutical guidance involves an educational
I02.233.332
Sponsors
Universidade Federal do Rio Grande do Norte
Secretaria de Estado da Saúde Pública do Rio Grande do Norte - SESAP
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Both sexes. Aged 18 years or older. Confirmed diagnosis of Asthma through spirometry. Patients currently using or starting the use of a dry powder inhaler (Aerolizer, Turbuhaler) and/or inhalation solution (Respimat system) on D0. Informed and voluntary consent to participate in the clinical trial
Exclusion criteria
Exclusion criteria: Conditions that may influence the learning of the inhalation technique (psychiatric, neurological, or rheumatological disorders). Presence of respiratory diseases other than asthma. Ongoing viral or bacterial respiratory infection. Dependency on third parties for DI handling. Hearing impairment. Severe visual impairment. Treatment with a different DI other than Aerolizer, Turbuhaler, and Respimat. Active smoking. Undergoing respiratory physiotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To confirm the effectiveness of pharmaceutical guidance and its potential community-level impact | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected | — |
Countries
Brazil
Contacts
Public ContactRodrigo Diniz
Universidade Federal do Rio Grande do Norte
Outcome results
None listed